Moleculin Biotech ( (MBRX) ) has shared an update.
Moleculin Biotech, Inc. has announced encouraging in vivo efficacy data for Annamycin in treating lung metastatic models of sarcoma, highlighting its significant inhibition of tumor growth and improved survival rates without the cardiotoxicity that limits the use of many anthracyclines. These promising results, presented at the International Association for the Study of Lung Cancer’s World Conference, reinforce Annamycin’s potential as a treatment for various types of cancer, including those resistant to other therapies. With ongoing clinical trials and FDA Fast Track and Orphan Drug Designations for certain cancers, Annamycin is positioned as a hopeful new player in the fight against hard-to-treat tumors.
For an in-depth examination of MBRX stock, go to TipRanks’ Stock Analysis page.
